Jacobs Levy Equity Management
MRSN

Jacobs Levy Equity Management’s Mersana Therapeutics MRSN Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,318
Closed -$395K – 1056
2025
Q2 		$395K Sell
53,318
-7
-0% -$62 ﹤0.01% 917
2025
Q1 		$459K Buy
53,325
+8,845
+20% +$136K ﹤0.01% 928
2024
Q4 		$1.59M Buy
44,480
+4,758
+12% +$246K 0.01% 644
2024
Q3 		$1.88M Buy
39,722
+20,298
+104% +$896K 0.01% 617
2024
Q2 		$976K Sell
19,424
-12,971
-40% -$938K ﹤0.01% 748
2024
Q1 		$3.63M Sell
32,395
-4,829
-13% -$480K 0.02% 487
2023
Q4 		$2.16M Buy
+37,224
New +$1.5M 0.01% 591
2023
Q2 		– Sell
-2,636
Closed -$271K – 1042
2023
Q1 		$271K Sell
2,636
-17,490
-87% -$2.45M ﹤0.01% 880
2022
Q4 		$2.95M Buy
20,126
+3,979
+25% +$672K 0.02% 481
2022
Q3 		$2.73M Buy
+16,147
New +$2.62M 0.02% 504
2019
Q4 		– Sell
-6,116
Closed -$242K – 1043
2019
Q3 		$242K Sell
6,116
-559
-8% -$40.6K ﹤0.01% 812
2019
Q2 		$676K Buy
+6,675
New +$786K 0.01% 701
2019
Q1 		– Sell
-1,547
Closed -$158K – 1004
2018
Q4 		$158K Buy
+1,547
New +$245K ﹤0.01% 911

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jacobs Levy Equity Management's MRSN Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 53,318 shares — an estimated $395K sold.

Jacobs Levy Equity Management first reported a position in MRSN in Q4 2018 and held it in 13 quarters. The position peaked at $3.63M in Q1 2024. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 53,318 Mersana Therapeutics shares in Q3 2025, an estimated $395K.
  • Jacobs Levy Equity Management first reported a position in Mersana Therapeutics in Q4 2018 and held it in 13 quarters.
  • Jacobs Levy Equity Management's Mersana Therapeutics position peaked at $3.63M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.